- age < 18 - pregnant - allergic to experimental drugs - the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); - copd or end-stage lung disease requires home oxygen therapy - expected survival time not exceeding 48 hours - participated in other clinical intervention trials within the last 3 months - autoimmune diseases - a history of organ, bone marrow or hematopoietic stem cell transplantation - received radiotherapy and chemotherapy for malignant tumor within 6 months - hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) - patients receiving anti-hcv treatment - 90 days of retinal detachment or eye surgery - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis - the competent physician considered it inappropriate to participate in the study

- age < 18 - pregnant - allergic to experimental drugs - the underlying disease is very serious and the expected survival time is less than 6 months (such as advanced malignant tumor); - copd or end-stage lung disease requires home oxygen therapy - expected survival time not exceeding 48 hours - participated in other clinical intervention trials within the last 3 months - autoimmune diseases - a history of organ, bone marrow or hematopoietic stem cell transplantation - received radiotherapy and chemotherapy for malignant tumor within 6 months - hiv infected patients or diagnosed with acquired immunodeficiency within the past year (cd4 t cells <=200/mm3) - patients receiving anti-hcv treatment - 90 days of retinal detachment or eye surgery - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis - the competent physician considered it inappropriate to participate in the study